Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsXPAR:ABLD -3.17%49 EV-to-EBITDA is 39.65 as of Aug. 17, 2026, which is 176% above its 10-year median of 14.34. GuruFocus rates XPAR:ABLD with a GF Score™ of 49/100 and a GF Value™ of €8.15 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 510 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 89.41% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ABL Diagnostics's enterprise value is €40.17 Mil.
ABL Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.01 Mil. Therefore, ABL Diagnostics's EV-to-EBITDA for today is 39.65.
The historical rank and industry rank for ABL Diagnostics's EV-to-EBITDA or its related term are showing as below:
XPAR:ABLD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.02 Med: 14.34 Max: 3501.11
Current: 39.65
During the past 13 years, the highest EV-to-EBITDA of ABL Diagnostics was 3501.11. The lowest was -22.02. And the median was 14.34.
XPAR:ABLD's EV-to-EBITDA is ranked worse than 89.41% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 10.685
vs XPAR:ABLD: 39.65
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ABL Diagnostics's PE Ratio (TTM) for today is calculated as:
ABL Diagnostics's share price for today is €2.44.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.061.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ABL Diagnostics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, ABL Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's EV-to-EBITDA falls into.
ABL Diagnostics's current Enterprise Value is €40.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a EV-to-EBITDA of 39.65 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ABL Diagnostics. This is 176% above median its historical median of 14.34. According to the industry distribution chart, ABL Diagnostics ranks #456 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 89.4%.
Is ABL Diagnostics' EV-to-EBITDA too high?
ABL Diagnostics' current EV-to-EBITDA of 39.65 is 176% above median its 10-year median of 14.34. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.69. ABL Diagnostics' value of 39.65 is 271.1% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #456 out of 510 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, ABL Diagnostics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #456 out of 510 companies for EV-to-EBITDA. This places ABL Diagnostics in the lower half of its industry. The industry median EV-to-EBITDA is 10.69. ABL Diagnostics' value of 39.65 is 271.1% above this benchmark. While the company's 10-year median is 14.34 vs. the industry median of 10.69, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.69, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current EV-to-EBITDA of 39.65 is 271.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ABL Diagnostics. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current EV-to-EBITDA is 39.65, which is 176% above median its own 10-year median of 14.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.15, compared to a current price of €2.44 — trading 70.1% below its estimated fair value. The current EV-to-EBITDA is 39.65, which is 176% above median its 10-year median of 14.34 and 271.1% above the Healthcare Providers & Services industry median of 10.69. ABL Diagnostics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current EV-to-EBITDA is 39.65 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.44 is trading 70.1% below its estimated GF Value™ of €8.15.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
EV-to-EBITDA: 39.65 (176% above median its 10-year median of 14.34)
GF Value™: €8.15 vs. price of €2.44 (70.1% below fair value)
Industry Position: 271.1% above the Healthcare Providers & Services median (#456 of 510)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
49GF Score
Get the complete analysis for XPAR:ABLD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
